title: Low-dose rate brachytherapy with I-125 seeds has an excellent 5-year outcome with few side effects in patients with low-risk prostate cancer.
abstract: BACKGROUND
  Low-dose rate brachytherapy (LDR-BT) has been used in Sweden for more than a decade for treatment of low-risk prostate cancer. This study presents the outcome for patients treated with LDR-BT at a single institution with focus on the association between dose and biochemical failure-free survival (BFFS).
  
  
  METHODS
  In total 195 patients were treated with LDR-BT between 2004 and 2008. The patients were followed systematically for side effects for at least one year. PSA levels were followed regularly from three months and for at least five years. Outcome was analyzed in relation to clinical variables at baseline and to radiotherapy data.
  
  
  RESULTS
  Kaplan-Meier estimated BFFS at five years was 95.7%. Dose to the prostate in terms of D90% was significantly associated with BFFS [HR 0.90 (95%CI 0.83-0.96), p = 0.002].
  
  
  CONCLUSIONS
  Out data confirmed that absorbed dose is a predictive factor for BFFS for low-risk patients without androgen deprivation therapy. With our treatment routines and dosimetry, a D90% in the range of 170-180 Gy gives excellent outcomes with acceptable toxicity for patients with low-risk prostate cancer.
authors.affiliation: a Department of Oncology and Radiation Physics , Skåne University Hospital, Lund University , Lund , Sweden ;
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Rasmusson
authors.affiliation: a Department of Oncology and Radiation Physics , Skåne University Hospital, Lund University , Lund , Sweden ;
authors.forename: Adalsteinn
authors.initials: A
authors.lastname: Gunnlaugsson
authors.affiliation: a Department of Oncology and Radiation Physics , Skåne University Hospital, Lund University , Lund , Sweden ;
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Kjellén
authors.affiliation: a Department of Oncology and Radiation Physics , Skåne University Hospital, Lund University , Lund , Sweden ;
authors.forename: Per
authors.initials: P
authors.lastname: Nilsson
authors.affiliation: a Department of Oncology and Radiation Physics , Skåne University Hospital, Lund University , Lund , Sweden ;
authors.forename: Margret
authors.initials: M
authors.lastname: Einarsdottir
authors.affiliation: a Department of Oncology and Radiation Physics , Skåne University Hospital, Lund University , Lund , Sweden ;
authors.forename: Elinore
authors.initials: E
authors.lastname: Wieslander
authors.affiliation: b Department of Nursing , Umeå University , Umeå , Sweden ;
authors.forename: Per
authors.initials: P
authors.lastname: Fransson
authors.affiliation: c Department of Surgery and Urology , Skåne University Hospital , Malmö , Sweden.
authors.forename: Göran
authors.initials: G
authors.lastname: Ahlgen
authors.affiliation: a Department of Oncology and Radiation Physics , Skåne University Hospital, Lund University , Lund , Sweden ;
authors.forename: René
authors.initials: R
authors.lastname: Blom
mesh_terms: D000368:Aged; D001918:Brachytherapy / Q000009:adverse effects* / Q000379:methods*; D018572:Disease-Free Survival; D007172:Erectile Dysfunction / Q000209:etiology; D005242:Fecal Incontinence / Q000209:etiology; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000628:therapy; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D012307:Risk Factors; D016896:Treatment Outcome; D053202:Urinary Incontinence, Urge / Q000209:etiology
chemical_list: D007457:Iodine Radioisotopes